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http://www.biomedcentral.com/1472-6874/13/8RESEARCH ARTICLE Open AccessViews of general practitioners on the role of CA125
in primary care to diagnose ovarian cancer
Esther L Moss1, Alison Moran2, Timothy M Reynolds3 and Helen Stokes-Lampard4*Abstract
Background: NICE guidance on the investigation and treatment of ovarian cancer advocates that the tumour
marker CA125 should be the first line investigation for women suspected of having ovarian cancer.
Methods: An internet-based survey, of primary care doctors in the West Midlands, was conducted in order to
ascertain the views of general practitioners (GPs) of NICE guidance on the use of CA125 to triage suspected ovarian
cancer cancers and the impact that this may have on referral pathways.
Results: In total 258 GPs responded to the questionnaire. Although 219 (84.9%) responders reported awareness of
the NICE guidance only 146 (56.6%) had personally read the document. The majority 187 (72.5%) of respondents
anticipated that their use of CA125 would increase as a result of the new guidance. Abdominal bloating
(>50 years), persistent abdominal distension and the presence of an abdominal or pelvic mass/swelling were the
symptoms felt to be most associated with ovarian cancer. When questioned on the management of a woman with
a raised CA125 the majority of respondents reported that a normal ultrasound scan would not stop an urgent secondary
care referral if the CA125 was raised. There was no significant difference in the opinions of GPs with <5 years primary
care experience compared to GPs with 6+ years.
Conclusion: The symptoms associated with ovarian cancer are well understood by the GPs that responded however, a
coordinated programme of education and training is needed for GPs on the role of CA125 in ovarian cancer, in addition
to clearly defined referral pathways, in order to address a likely significant increase in suspected ovarian cancer referrals
to secondary care, most of whom will not have ovarian cancer.
Keywords: Ovarian cancer, CA125, Tumour marker, Primary careBackground
Recently published NICE guidance relating to the inves-
tigation and treatment of ovarian cancer [1] advocates
increased use of serum CA125 in primary care, in order
to improve the detection of ovarian cancer. Despite the
large numbers needed to detect a single cancer, NICE
concluded that, based on health economic evaluations,
serum CA125 should be the first test performed on
women with symptoms suggestive of ovarian cancer.
CA125 is an acute phase reactant which can be raised
in benign processes as a result of inflammation or infec-
tion [2]. There are very few published studies investigat-
ing the role of CA125 in primary care as compared to
secondary care and screening populations. CA125 has* Correspondence: h.j.stokeslampard@bham.ac.uk
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reproduction in any medium, provided the oryet to be shown to function as an effective screening tool
by detecting early stage disease or by reducing ovarian
cancer mortality [3]. An understanding of the low sensi-
tivity and false positive associations of CA125 amongst
doctors working in surgical, medical and primary care
specialties has previously been shown to be poor [4].
We conducted an internet-based survey of primary
care doctors in the West Midlands, in October 2011.
The aim of the study was to ascertain the views of gen-
eral practitioners (GPs) of NICE guidance on the use of
CA125 to triage suspected ovarian cancer cancers and
the impact that this may have on referral pathways.Methods
A questionnaire was designed using the internet-based
survey tool ‘Survey Monkey’ in order to facilitate com-
pletion and increase response rate whilst minimizingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographics of study population (n=258)
Number (percentage in brackets)
Gender
Male 99 (38.4)
Female 156 (60.5)
Experience
GP in training 38 (14.7)
GP <5 years 72 (27.9)
GP 6-10 years 39 (15.1)
GP >10 years 109 (42.2)
Location of practice
Rural 34 (13.2)
Suburban 66 (25.6)
Urban 102 (39.5)
Mixed 55 (21.3)
Affluence of practice area
Affluent 46 (17.8)
Average 122 (47.3)
Deprived 88 (34.1)
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surveys (Additional file 1). Information was gathered on
GPs’ personal clinical experience, the number of ovarian
cancer cases they had managed over the past 2 years and
their views on the symptoms associated with ovarian can-
cer. Two questions aimed to investigate GPs’ management
preferences when presented with a woman reporting
symptoms that may have been due to ovarian cancer.
The survey was piloted amongst a group of 10 General
Practitioners with an interest in gynaecological malig-
nancy, and their comments led to modifications of the
survey prior to its general distribution. After discussion
with the local research and development representative
the study was classified as service evaluation and as such
did not require ethical approval. A single email message
containing a link to the survey was sent out in an email
to all GPs on the Royal College of General Practitioners
Midland Faculty database, by Faculty administrators to
preserve GP confidentiality. No reminder emails were
sent, no measurement of accuracy of the email database
was available and no incentive for completion of the
study was offered.
Results were collated automatically, analyzed and the
responses of GPs with less than 5 years experience in
primary care compared with GPs who had 6+ more
years of experience by determining difference in confi-
dence intervals for binomial proportions using the Nor-
mal approximation interval method.
Results
In total 258 GPs responded to the questionnaire out of a
total of 3,230 that were sent a single email explaining
the project and containing a web link for the survey, giv-
ing a response rate of 8.0%.
The breakdown of the number of years in primary care
and the location and demographic breakdown of the
respondents’ practices is contained in Table 1. The num-
ber of ovarian cancer cases seen by the respondents over
the previous 2 years was very low: 112 (43.4%) reported
2-4 cases, 70 (27.1%) one case and 60 (23.3%) no cases.
The number of suspected cases referred to secondary
care by the respondents over that same time period was
also very low: 150 (58.1%) reported no referral, 70
(27.1%) one referral and 29 (11.2%) two referrals. CA125
was used to help with making the diagnosis in the ma-
jority of cases: 63 (42.6%) every time, 38 (25.7%) some of
the time but not used 45 (30.4%) cases.
Although 219 (84.9%) responders reported awareness of
the NICE guidance only 146 (56.6%) had personally read
the document. The majority, 187 (72.5%), anticipated that
their use of CA125 would increase as a result of the
new guidance.
The symptoms felt to be strongly associated with ovarian
cancer were abdominal bloating (>50 years), persistentabdominal distension and the presence of an abdominal or
pelvic mass/swelling (Table 2). These four symptoms also
received the highest scores for the symptoms that would
prompt the respondent to perform a CA125 (Table 3).
When comparing the opinions of GPs with <5 years and
with 6+ years experience in primary care there was no sig-
nificant difference in their opinions on the symptoms
associated with ovarian cancer or on the symptoms that
would prompt a CA125.
The highest rated additional factors which respondents
felt would make ovarian cancer more likely were: being
postmenopausal, a family history of breast or ovarian
cancer or a personal history of breast cancer (Table 4).
GPs with 6+ years of experience did not rate breast
cancer as great an associated factor as did GPs with
less experience: scores for ‘yes definitely’ for personal
history of breast cancer 39% (95% CI 30.9-47.9%) ver-
sus 63% (95% CI 52.8-72.2%) (95% CI for difference in
proportion 6.2-40.1%) and for family history of breast
cancer 27% (95% CI 19.2-34.7%) versus 53% (95% CI
42.5-62.8%) (95% CI for difference in proportion 8.9-
42.5%) for 6+ years compared to <5 years respectively.
The majority of respondents reported that they would
perform a speculum/pelvic examination of a patient in
whom ovarian cancer was suspected prior to referral, 88
(38.3%) every time, 96 (41.7%) most cases, 39 (17.0%)
rarely compared to 7 (3.0%) never. There was no signifi-
cant difference in the answers given between the less
and more experienced GPs, χ2 = 1.75; p=0.94.
When investigating the management of a woman
presenting with persistent abdominal bloating for the past
Table 2 Responses to the question ‘What symptoms would make you consider ovarian cancer as a possible diagnosis?’
Symptom Yes definitely Probably Possibly Very unlikely No
Abdominal pain 49 (21.5) 51 (23.3) 118 (51.8) 9 (3.9) 1 (0.4)
Bloating (<50 years) 35 (15.8) 38 (17.2) 110 (49.8) 36 (16.3) 2 (0.9)
Bloating (>50 years) 105 (46.1) 64 (28.1) 55 (24.1) 4 (1.8) 0
Abdominal distension (intermittent) 25 (11.2) 43 (19.2) 111 (49.6) 43 (19.2) 2 (0.9)
Abdominal distension (persistent) 144 (63.7) 51 (22.6) 31 (13.7) 0 0
Abdominal mass/swelling 148 (64.9) 52 (22.8) 25 (11.0) 3 (1.3) 0
Pelvic mass/swelling 194 (85.5) 25 (11.0) 7 (3.1) 1 (0.4) 0
Urinary frequency/urgency 26 (11.4) 52 (9.6) 119 (52.2) 29 (12.7) 2 (0.9)
Abnormal vaginal bleeding (pre/perimenopause) 31 (13.6) 47 (20.6) 96 (42.1) 50 (21.9) 4 (1.8)
Postmenopausal bleeding 38 (16.7) 33 (14.5) 97 (42.7) 51 (22.5) 8 (3.5)
Rectal bleeding 2 (0.9) 6 (2.7) 61 (27.0) 135 (59.7) 22 (9.7)
Loss of appetite 47 (20.7) 61 (26.9) 101 (44.5) 16 (7.0) 2 (0.9)
Unexplained weight loss 83 (36.4) 60 (26.3) 80 (35.1) 3 (1.3) 2 (0.9)
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majority of GPs reported that they would initiate investiga-
tion in the community for a mildly raised CA125 (50) but
that a more abnormal CA125 (200) would result in a refer-
ral to secondary care without out waiting for an ultrasound
scan of the pelvis (Table 5). Even if an ultrasound scan of
the pelvis demonstrated no abnormality, only a small pro-
portion of GPs would be happy to watch and wait if the
CA125 was raised and, if the CA125 was 200, over half
would refer women using the suspected cancer pathway.
Discussion
Ovarian cancer was previously known as the ‘silent
killer’ but studies have shown that it is associated with
symptoms in 93% of cases before diagnosis [5]. The
positive predictive value of individual symptoms, how-
ever, is very low, including the symptoms highlightedTable 3 Responses to the question ‘What symptoms would pr
Symptom Yes definitely
Abdominal pain 33 (15.1)
Bloating (<50 years) 34 (15.7)
Bloating (>50 years) 105 (47.1)
Abdominal distension (intermittent) 23 (10.6)
Abdominal distension (persistent) 155 (69.5)
Abdominal mass/swelling 158 (70.9)
Urinary frequency/urgency 22 (9.9)
Abnormal vaginal bleeding (pre/perimenopause) 20 (9.1)
Postmenopausal bleeding 28 (12.7)
Rectal bleeding 1 (0.5)
Loss of appetite 44 (20.0)
Unexplained weight loss 75 (34.2)in this study as being ‘yes definitely’ associated with
ovarian cancer, abdominal bloating 0.01-0.3% [6-9], ab-
dominal distension 0.07-2.26% [6-10] and abdominal
mass/swelling 0.48-11% [9,10]. Algorithms have been
introduced to try and improve detection using symptoms.
The Goff symptom index [11] has been shown to increase
the specificity for the detection of ovarian cancer as
compared to any symptoms but this is at the expense of
sensitivity. In this study the GPs that responded to this
questionnaire were aware of the typical symptoms
associated with ovarian cancer (bloating (>50 years), per-
sistent abdominal distension and abdominal/pelvic mass or
swelling) and it is these symptoms that would prompt
them to order a CA125. The symptom of ‘altered bowel
habit’ was not specifically included in the questionnaire
since it was not possible to include an exhaustive list of all
the symptoms associated with ovarian cancer and the GPompt you to request a CA125?’
Probably Possibly Very unlikely No
45 (20.5) 106 (48.4) 22 (10.0) 13 (5.9)
42 (19.4) 92 (42.6) 36 (16.7) 12 (5.6)
69 (30.9) 39 (17.5) 4 (1.8) 6 (2.7)
53 (24.5) 98 (45.4) 31 (14.4) 11 (5.1)
45 (20.2) 17 (7.6) 0 6 (2.7)
40 (17.9) 18 (8.1) 1 (0.4) 6 (2.7)
32 (14.3) 106 (47.5) 51 (22.9) 12 (5.4)
36 (16.4) 92 (42.0) 58 (26.5) 13 (5.9)
35 (15.8) 79 (35.7) 62 (28.1) 17 (7.7)
4 (1.8) 52 (23.6) 124 (56.4) 39 (17.7)
46 (20.9) 101 (45.9) 20 (9.1) 9 (4.1)
68 (31.1) 64 (29.2) 6 (2.7) 6 (2.7)
Table 4 General practitioners’ views on ‘What additional factors would make you consider ovarian cancer to be more
likely?’
Yes definitely Probably Possibly Very unlikely No
Postmenopausal 111(50.0) 71 (32.0) 28 (12.6) 8 (3.6) 4(1.8)
Early menopause 20 (9.4) 34 (16.0) 77 (36.3) 54 (25.5) 27 (12.7)
History of endometriosis 6 (2.8) 11 (5.1) 77 (35.5) 86 (39.6) 37 (17.1)
History of infertility 23 (10.6) 30 (13.8) 81 (37.3) 56 (25.8) 27 (12.4)
Nulliparity 48 (22.3) 42 (19.5) 88 (40.9) 25 (11.6) 12 (5.6)
Multiparity 1 (0.5) 7 (3.3) 58 (27.0) 105 (48.8) 44 (20.5)
FH ovarian cancer 171 (75.7) 37 (16.4) 18 (8.0) 0 0
PH breast cancer 110 (49.3) 66 (29.6) 42 (18.8) 3 (1.3) 2 (0.9)
FH breast cancer 83 (37.9) 66 (30.1) 58 (26.5) 10 (4.6) 2 (0.9)
Obesity (BMI>40) 57 (25.8) 80 (36.2) 66 (29.9) 13 (5.9) 5 (2.3)
HRT use 17 (7.7) 31 (14.1) 86 (39.1) 59 (26.8) 27 (12.3)
Previous hormonal contraception 5 (2.3) 19 (8.6) 48 (21.7) 97 (43.9) 52 (23.5)
No previous hormonal contraception 18 (8.2) 25 (11.4) 84 (38.2) 56 (25.5) 37 (16.8)
FH=family history, PH=personal history, HRT = hormone replacement therapy.
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ral to investigate the possibility of a colorectal malignancy.
The aim of questioning GPs on their management of a
woman with no family history of ovarian cancer presenting
with persistent abdominal bloating for the past 1 month
was to try and determine their views and practice on refer-
ral pathways at different levels of CA125. We have shown
that the higher the CA125 and being postmenopausal
would increase the likelihood of referral to secondary care.
We have also shown that although they would be happy to
order an ultrasound to investigate a mildly raised CA125
(50), a higher result (200) would prompt a direct referral
on a suspected cancer pathway without waiting forTable 5 General practitioners’ views on the management of a
presenting with persistent abdominal bloating for the past 1
General gynaecology
referral
Two w
Premenopausal (<50 years)
CA125 - 50 13 (6.7)
CA125 - 200 13 (6.7)
CA125 - 50/USS nad 63 (33.0)
CA125 – 200/USS nad 49 (25.5)
CA125 nad/USS nad 19 (9.7)
Postmenopausal (>50 years)
CA125 - 50 19 (10.3)
CA125 - 200 10 (5.4)
CA125 - 50/USS nad 71 (38.8)
CA125 – 200/USS nad 32 (17.6)
CA125 nad/USS nad 23 (12.8)
USS = ultrasound scan, nad = no abnormality detected, 2 week wait = suspected caimaging. Our results show that a normal ultrasound would
not stop referrals to secondary care if CA125 was raised,
the majority stating that they would use a suspected cancer
pathway if the CA125 was 200. This is in contrast to the
NICE ‘Detection in primary care’ algorithm [12], which
advises that a CA125 ≥35lU/ml and an ultrasound of the
abdomen and pelvis suggestive of ovarian cancer should re-
sult in an urgent referral. The advised pathway of assess-
ment for other clinical causes of a raised CA125 does not
appear to be the management option of choice and may re-
flect the fact that CA125 is primarily known as a tumour
marker for ovarian cancer and its false positive associations
are not well known by GPs [4].woman with no family history of ovarian cancer
month
eek wait/ gynaecological
oncology referral Order USS Watch and wait
36 (18.5) 140 (71.8) 4 (2.1)
126 (64.9) 53 (27.3) 0
41 (21.5) - 36 (18.8)
113 (58.9) - 2 (1.0)
8 (4.1) - 51 (25.6)
53 (28.8) 107 (58.2) 4 (1.6)
133 (71.9) 41 (22.2) 0
51 (27.9) - 23 (12.6)
112 (61.5) - 2 (1.1)
13 (7.2) - 28 (15.6)
ncer referral to gynaecology/gynaecolgical oncology.
Moss et al. BMC Women's Health 2013, 13:8 Page 5 of 6
http://www.biomedcentral.com/1472-6874/13/8The recently introduced guidance has given cause for
concerns from both the oncology and primary care com-
munities. Gynaecological oncologists highlighted the
poor sensitivity of CA125 in early stage disease and in
non-serous subtypes [13], which could result in false re-
assurance from a normal value and in turn would delay
rather than expedite a diagnosis [14]. Cave [15] reported
on behalf of general practitioners by asking for guidance
to help in the interpretation of CA125 in primary care.
He also highlighted the lack of general practitioner in-
volvement in development of the guidance, only one
representative on the NICE guideline development
group compared to six secondary care specialists. Al-
though the reasoning behind the new guidance was lo-
gical, in an attempt to reduce the time from first
presentation to diagnosis of ovarian cancer, there remain
serious concerns. Without a fuller understanding of the
true potential of CA125 as a tumour marker in primary
care and support for general practitioners on its inter-
pretation, the number of women referred to secondary
care with suspected ovarian cancer will increase dramat-
ically, as has been highlighted by this study. This will ei-
ther require greater resources in secondary care to
investigate or potentially undermine the rapid access ser-
vice for “real cases”. There is also the concern that a nor-
mal CA125 result may now be taken as having excluded
ovarian cancer and therefore further investigations or im-
aging will be delayed or not be undertaken until the dis-
ease is further advanced. On the other hand, it is
becoming increasingly accepted that the most common
and lethal subtype of ovarian cancer, high-grade serous,
is likely to originate from the fallopian tube rather than
the ovary. This would have a dramatic effect on the ra-
tionale for screening since detecting an abnormality in
the ovary would be identifying metastatic disease and as
such would not alter the long-term outcome if the diag-
nosis was delayed while waiting for investigations.
It is important to be mindful of the patient in the
midst of this process. Calculations by NICE estimate that
around 1 in 100 women with a positive CA125 or ultra-
sound scan will have ovarian cancer [12], therefore for
every 100 women referred, 99 will not have ovarian can-
cer. The negative psychological impact on women re-
ferred needs to be considered since many will be
informed that a raised CA125 means that they probably
have ovarian cancer.
This study was a pragmatic, single email invitation on-
line survey and, as such, has a very low response rate.
The combination of no financial incentive, a rare clinical
presentation in Primary Care and no follow up or re-
minder emails all contributed to the low response rate.
Therefore this study cannot be taken as being represen-
tative of the views of GPs as a whole, however, it is rea-
sonable to assume that the majority of GPs taking thetime to complete the survey had a greater than average
interest in the subject matter and consequently probably
represent a ‘better informed’ GP population overall.
Thus our findings are likely to be conservative and repre-
sent best current practice. Surveys are always subject to
bias and we have not used any validated questionnaires
or instruments, however we believe that we have revealed
important and useful information about current thinking
in primary care. This has a direct impact on increasing
secondary care referrals and thus should inform future
research into this subject.
Conclusion
In conclusion, the use of CA125 as a primary diagnostic
tool for suspected ovarian cancer has yet to be shown to
be of benefit in a clinical trial, either in the primary or
secondary care setting. The introduction of NICE guid-
ance advocating its use is both premature and associated
with potential risks. Without a coordinated programme
of education and training for GPs, in addition to clearly
defined referral pathways, it is likely that there will be a
significant increase in suspected ovarian cancer referrals
to secondary care, most of whom will not have ovarian
cancer. Without the benefit of trial data only time will
tell whether such a policy will actually improve the early
detection and therefore survival of ovarian cancer
patients or merely result in increased investigation and
anxiety in many women.
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